Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody
محل انتشار: پنجمین کنفرانس ملی توسعه فناوری نانو
سال انتشار: 1399
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 197
فایل این مقاله در 10 صفحه با فرمت PDF قابل دریافت می باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
NANOTEC05_004
تاریخ نمایه سازی: 28 خرداد 1400
چکیده مقاله:
Epidermal growth factor receptor variant III (EGFRvIII) is the most common variant of the EGF receptor in many human tumors. This variant is tumor specific and highly immunogenic, thus, it can be used as a target for targeted drug delivery toward tumor cells. The major aim of this study was to develop an EGFRvIII-mediated drug delivery system by anti-EGFRvIII monoclonal antibody (MAb) conjugated to doxorubicin (Dox)-loaded nanostructured lipid carriers (NLC) to enhance the targeting specificity and cytotoxic effect of Dox on EGFRvIII-overexpressing cell line. In our study, Dox was chosen as a hydrophobic cytotoxic drug and drug-loaded nanostructured lipid carriers (Dox-NLC) was prepared by solvent emulsification/evaporation method. In order to conjugate anti-EGFRvIII MAb to Dox-NLC, DSPEPEG۲۰۰۰-NHS (۱,۲-distearoylphosphatidylethanolamine–polyethylene glycol ۲۰۰۰–NHS) was used as a linker. Physicochemical characteristics of antibody conjugated Dox-NLC (MAb-Dox-NLC), including particle size, zeta potential, entrapment efficiency and in vitro Dox release were investigated. Cytotoxicity of MAb-Dox-NLC against NIH-۳T۳ and HC۲ ۲۰d۲/c (EGFRvIII-transfected NIH-۳T۳) cell lines was evaluated. The MAb-Dox-NLC appeared to enhance the cytotoxic activity of targeted NLC against HC۲ ۲۰d۲/c cells. The cellular uptake percentage of targeted NLC by HC۲ ۲۰d۲/c cells was higher than that of NIH-۳T۳ cells, indicating that EGFRvIII can specifically target HC۲ ۲۰d۲/c cells. In conclusion, antiEGFRvIII MAb-targeted NLC may be considered as an effective nanocarrier for targeted drug delivery.
کلیدواژه ها:
نویسندگان
Saeideh Abdolahpour
Department of Medical Biochemistry Faculty of Medicine, Tehran University of Medical Sciences Tehran, Iran
Maliheh Paknejad
Department of Medical Biochemistry Faculty of Medicine, Tehran University of Medical Sciences Tehran, Iran
Tayebeh Toliyat
Department of Pharmaceutics Faculty of Pharmacy, Tehran University of Medical Sciences Tehran, Iran